| 1 |
35216503 | Neuroprotective Effects of the DPP4 Inhibitor Vildagliptin in In Vivo and In Vitro Models of Parkinson's Disease. | 2022 Feb 21 |
3 |
| 2 |
35272176 | Therapeutic equivalence of vildagliptin 100 mg once daily modified release to 50 mg twice daily immediate release formulation: An open-label, randomized, two-period, single- and multiple-dose, 6-day crossover study. | 2022 Mar |
3 |
| 3 |
35370321 | Physicochemical Properties and Methods of Analysis of Vildagliptin (Review). | 2022 |
2 |
| 4 |
32242496 | Pharmacophore- based virtual screening, 3D- QSAR, molecular docking approach for identification of potential dipeptidyl peptidase IV inhibitors. | 2021 Apr |
1 |
| 5 |
32310854 | Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients. | 2021 Jan |
2 |
| 6 |
33068301 | Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control. | 2021 Mar |
1 |
| 7 |
33573656 | The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study. | 2021 Feb 11 |
1 |
| 8 |
34384428 | Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors. | 2021 Aug 12 |
1 |
| 9 |
34484112 | Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. | 2021 |
2 |
| 10 |
34577104 | Comprehensive Insight into Chemical Stability of Important Antidiabetic Drug Vildagliptin Using Chromatography (LC-UV and UHPLC-DAD-MS) and Spectroscopy (Mid-IR and NIR with PCA). | 2021 Sep 16 |
2 |
| 11 |
31689132 | Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin. | 2020 Jan |
1 |
| 12 |
31885117 | Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan. | 2020 Mar |
2 |
| 13 |
32014700 | Cognitive and metabolic outcomes of vildagliptin addition to the therapy in patients with type 2 diabetes mellitus: 26 week follow-up study. | 2020 May - Jun |
1 |
| 14 |
32093712 | Aberrant expression of miR-214 is associated with obesity-induced insulin resistance as a biomarker and therapeutic. | 2020 Feb 24 |
1 |
| 15 |
32218354 | Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis. | 2020 Mar 25 |
2 |
| 16 |
32228183 | Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan. | 2020 May |
2 |
| 17 |
32731178 | Vildagliptin, a CD26/DPP4 inhibitor, ameliorates bleomycin-induced pulmonary fibrosis via regulating the extracellular matrix. | 2020 Oct |
6 |
| 18 |
32746479 | Analytical Method Development and Validation of UV-visible Spectrophotometric Method for the Estimation of Vildagliptin in Gastric Medium. | 2020 Sep |
2 |
| 19 |
32873667 | Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol. | 2020 Sep 1 |
1 |
| 20 |
32956689 | Vildagliptin, a DPP-4 inhibitor, attenuates carbon tetrachloride-induced liver fibrosis by targeting ERK1/2, p38α, and NF-κB signaling. | 2020 Nov 15 |
1 |
| 21 |
32982353 | Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension. | 2020 |
1 |
| 22 |
33050169 | Acute Effects of Metformin and Vildagliptin after a Lipid-Rich Meal on Postprandial Microvascular Reactivity in Patients with Type 2 Diabetes and Obesity: A Randomized Trial. | 2020 Oct 9 |
1 |
| 23 |
29607626 | Drug fever and acute inflammation from hypercytokinemia triggered by dipeptidyl peptidase-4 inhibitor vildagliptin. | 2019 Jan |
2 |
| 24 |
30123993 | Vildagliptin Enhances Differentiation of Insulin Producing Cells from Adipose-Derived Mesenchymal Stem Cells. | 2019 Jan |
2 |
| 25 |
30444033 | Vildagliptin improves high glucose-induced endothelial mitochondrial dysfunction via inhibiting mitochondrial fission. | 2019 Feb |
1 |
| 26 |
30452909 | Vildagliptin reduced extracellular matrix degradation in human primary chondrocytes. | 2019 Feb 5 |
1 |
| 27 |
30519910 | Vildagliptin, an Anti-diabetic Drug of the DPP-4 Inhibitor, Induces Vasodilation via Kv Channel and SERCA Pump Activation in Aortic Smooth Muscle. | 2019 Jun |
1 |
| 28 |
30567879 | Gas-Phase Rearrangement of the O-Glucuronide of Vildagliptin Forms Product-Ion Fragments Suggesting Wrongly an N-Glucuronide. | 2019 Mar |
1 |
| 29 |
30624566 | Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes. | 2019 Feb 1 |
4 |
| 30 |
30828846 | Randomised clinical trial: the DPP-4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon-like peptide-1 plasma levels in healthy volunteers. | 2019 Apr |
1 |
| 31 |
30945564 | Vildagliptin inhibits high free fatty acid (FFA)-induced NLRP3 inflammasome activation in endothelial cells. | 2019 Dec |
1 |
| 32 |
31026379 | Protective effect of vildagliptin on TNF-α-induced chondrocyte senescence. | 2019 Jul |
2 |
| 33 |
31164969 | Placental extracellular vesicles express active dipeptidyl peptidase IV; levels are increased in gestational diabetes mellitus. | 2019 |
1 |
| 34 |
31169082 | Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics. | 2019 Mar |
1 |
| 35 |
31204117 | Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment. | 2019 Sep - Oct |
3 |
| 36 |
31275243 | DPP-4 Inhibition and the Path to Clinical Proof. | 2019 |
1 |
| 37 |
31275298 | Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid. | 2019 |
1 |
| 38 |
31324296 | Design, synthesis and evaluation of DNA nano-cubes as a core material protected by the alginate coating for oral administration of anti-diabetic drug. | 2019 Jul |
3 |
| 39 |
31336466 | Prevalence and association of co-morbidities in diabetic patients along with prescription patterns in Delhi-NCT, India. | 2019 Mar - Apr |
1 |
| 40 |
31792328 | DPP8 is a novel therapeutic target for multiple myeloma. | 2019 Dec 2 |
1 |
| 41 |
28418203 | Effectiveness of vildagliptin as add-on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real-world setting. | 2018 Jan |
1 |
| 42 |
29032139 | Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. | 2018 Jan |
1 |
| 43 |
29274348 | Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. | 2018 Jun |
2 |
| 44 |
29359260 | Clinical impact of oral antidiabetic medications in heart failure patients. | 2018 May |
1 |
| 45 |
29396374 | Efficacy of vildagliptin for prevention of postpartum diabetes in women with a recent history of insulin-requiring gestational diabetes: A phase II, randomized, double-blind, placebo-controlled study. | 2018 Mar |
1 |
| 46 |
29409972 | Inhibition of dipeptidyl peptidase IV prevents high fat diet-induced liver cancer angiogenesis by downregulating chemokine ligand 2. | 2018 Apr 28 |
1 |
| 47 |
29498469 | Different glucagon effects during DPP-4 inhibition versus SGLT-2 inhibition in metformin-treated type 2 diabetes patients. | 2018 Jul |
1 |
| 48 |
29679391 | Cardiovascular effects of sitagliptin - An anti-diabetes medicine. | 2018 Jul |
1 |
| 49 |
30172711 | Identification of a novel metabolite of vildagliptin in humans: Cysteine targets the nitrile moiety to form a thiazoline ring. | 2018 Oct |
2 |
| 50 |
30557974 | Linagliptin-related pancreatitis in a diabetic patient with biliary calculus: A case report. | 2018 Dec |
1 |